Radiation
Peptide Receptor Radionuclide Therapy (PRRT)
Peptide Receptor Radionuclide Therapy (PRRT) is a radiation therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Withdrawn1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 11 (100.0%)
Trials by Status
withdrawn133%
not_yet_recruiting133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruiting
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
NCT07538791
recruiting
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
NCT06510868
withdrawnphase_1
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
NCT05610826
Clinical Trials (3)
Showing 3 of 3 trials
NCT07538791
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
NCT06510868
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
NCT05610826Phase 1
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
All 3 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 3